Hannes Hahne

Hannes Hahne

Auto-generated profile, based on publicly available information

Hannes Hahne

OmicScouts GmbH, Freising, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
DWDongxue Wang
Dongxue Wang
BEBasak Eraslan
Basak Eraslan
TWThomas Wieland
Thomas Wieland
BHBjörn Hallström
Björn Hallström
THThomas Hopf
Thomas Hopf
BKBernhard Kuster
Bernhard Kuster
Genome‐, transcriptome‐ and proteome‐wide measurements provide insights into how biological systems are regulated. However, fundamental aspects relating to which human proteins exist, where they are expressed and in which quantities are not fully understood. Therefore, we generated a quantitative proteome and transcriptome abundance atlas of 29 paired healthy human tissues from the Human Protein Atlas project representing human genes by 18,072 transcripts and 13,640 proteins including 37 without prior protein‐level evidence. The analysis revealed that hundreds of proteins, particularly in testis, could not be detected even for highly expressed mRNAs, that few proteins show tissue‐specific expression, that strong differences between mRNA and protein quantities within and across tissues exist and that protein expression is often more stable across tissues than that of transcripts. Only 238 of 9,848 amino acid variants found by exome sequencing could be confidently detected at the protein level showing that proteogenomics remains challenging, needs better computational methods and requires rigorous validation. Many uses of this resource can be envisaged including the study of gene/protein expression regulation and biomarker specificity evaluation.

13 April 2020 in Nature Methods
Verified
Journal Article
Closed access
PDF file
AJAnna Jarzab
Anna Jarzab
NKNils Kurzawa
Nils Kurzawa
THThomas Hopf
Thomas Hopf
MMMatthias Moerch
Matthias Moerch
JZJana Zecha
Jana Zecha
BKBernhard Kuster
Bernhard Kuster

7 April 2023 in Science
Verified
Journal Article
Closed access
JZJana Zecha
Jana Zecha
FBFlorian P. Bayer
Florian P. Bayer
SWSvenja Wiechmann
Svenja Wiechmann
JWJulia Woortman
Julia Woortman
NBNicola Berner
Nicola Berner
BKBernhard Kuster
Bernhard Kuster
Although most cancer drugs modulate the activities of cellular pathways by changing posttranslational modifications (PTMs), little is known regarding the extent and the time- and dose-response characteristics of drug-regulated PTMs. In this work, we introduce a proteomic assay called decryptM that quantifies drug-PTM modulation for thousands of PTMs in cells to shed light on target engagement and drug mechanism of action. Examples range from detecting DNA damage by chemotherapeutics, to identifying drug-specific PTM signatures of kinase inhibitors, to demonstrating that rituximab kills CD20-positive B cells by overactivating B cell receptor signaling. DecryptM profiling of 31 cancer drugs in 13 cell lines demonstrates the broad applicability of the approach. The resulting 1.8 million dose-response curves are provided as an interactive molecular resource in ProteomicsDB.

1 July 2021 in Cell Reports
Verified
Journal Article
Open access
SDSebastian Dieter
Sebastian Dieter
CSChristine Siegl
Christine Siegl
PCPaula L. Codó
Paula L. Codó
MHMario Huerta
Mario Huerta
AOAnna L. Ostermann-Parucha
Anna L. Ostermann-Parucha
HGHanno Glimm
Hanno Glimm
Novel treatment options for metastatic colorectal cancer (CRC) are urgently needed to improve patient outcome. Here, we screen a library of non-characterized small molecules against a heterogeneous collection of patient-derived CRC spheroids. By prioritizing compounds with inhibitory activity in a subset of-but not all-spheroid cultures, NCT02 is identified as a candidate with minimal risk of non-specific toxicity. Mechanistically, we show that NCT02 acts as molecular glue that induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK and its complex partner CDK12. Knockout of CCNK or CDK12 decreases proliferation of CRC cells in vitro and tumor growth in vivo. Interestingly, sensitivity to pharmacological CCNK/CDK12 degradation is associated with TP53 deficiency and consensus molecular subtype 4 in vitro and in patient-derived xenografts. We thus demonstrate the efficacy of targeted CCNK/CDK12 degradation for a CRC subset, highlighting the potential of drug-induced proteolysis for difficult-to-treat types of cancer.

1 February 2019 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
BEBasak Eraslan
Basak Eraslan
DWDongxue Wang
Dongxue Wang
MGMirjana Gusic
Mirjana Gusic
PHProkisch Holger
Prokisch Holger
BHBjörn M Hallström
Björn M Hallström
JGJulien Gagneur
Julien Gagneur
Despite their importance in determining protein abundance, a comprehensive catalogue of sequence features controlling protein‐to‐mRNA (PTR) ratios and a quantification of their effects are still lacking. Here, we quantified PTR ratios for 11,575 proteins across 29 human tissues using matched transcriptomes and proteomes. We estimated by regression the contribution of known sequence determinants of protein synthesis and degradation in addition to 45 mRNA and 3 protein sequence motifs that we found by association testing. While PTR ratios span more than 2 orders of magnitude, our integrative model predicts PTR ratios at a median precision of 3.2‐fold. A reporter assay provided functional support for two novel UTR motifs, and an immobilized mRNA affinity competition‐binding assay identified motif‐specific bound proteins for one motif. Moreover, our integrative model led to a new metric of codon optimality that captures the effects of codon frequency on protein synthesis and degradation. Altogether, this study shows that a large fraction of PTR ratio variation in human tissues can be predicted from sequence, and it identifies many new candidate post‐transcriptional regulatory elements.

1 February 2010 in Protein Engineering, Design and Selection
Verified
Journal Article
Closed access
PDF file
LFLars Friedrich
Lars Friedrich
SSSTEFAN STANGL
STEFAN STANGL
HHHannes Hahne
Hannes Hahne
BKBernhard Kuster
Bernhard Kuster
PKPeter Köhler
Peter Köhler
Arne SkerraArne Skerra
Arne Skerra
Hsp70, the major stress-inducible member of the 70 kDa heat shock protein family, is frequently exposed on the plasma membrane of human tumours and, even more pronounced, on metastases but not detectable on normal tissues. The mouse monoclonal antibody cmHsp70.1, which recognizes a peptide epitope in the C-terminal substrate binding domain of both human and murine Hsp70, provides a promising reagent for the monitoring of Hsp70-positive tumours during cancer therapy. Here, we describe the variable domain sequences of the antibody produced by the hybridoma cell line and attempts to secrete the corresponding recombinant Fab fragment in Escherichia coli. Initially, the yield of soluble functional Fab fragment that could be purified from the periplasmic cell extract was extremely low, even when preparing different chimeric versions with constant domains of human or murine origin or with the light chain constant domain belonging to the κ or λ class. Surprisingly, this yield could be raised dramatically by more than a factor 100 in the presence of the folding helper plasmid pTUM4, which overexpresses two periplasmic disulphide oxido-reductases as well as two chaperones with proline-cis/trans-isomerase activity. Thus, more than 15 mg functional recombinant Fab fragment could be purified per litre E.coli culture from a bench top fermenter. This Fab fragment showed high and specific Hsp70 binding activity in ELISA and SPR measurements, revealing a dissociation constant of 35 nM. Notably, the Fab fragment sensitively recognizes the membrane-associated Hsp70 on tumour cell lines both in immunofluorescence microscopy and flow cytometry, thus showing potential for tumour detection in vitro and in vivo.